142 related articles for article (PubMed ID: 34980364)
1. Management of externally manufactured cell therapy products: the Mayo Clinic approach.
Wiltshire TD; Deeds MC; Radel DJ; Bornschlegl AM; Schmidt CS; Thebiay JM; Pelleymounter LL; Jacob EK; Stubbs JR; Gastineau DA; Dietz AB
Cytotherapy; 2022 Jan; 24(1):19-26. PubMed ID: 34980364
[TBL] [Abstract][Full Text] [Related]
2. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
3. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
4. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
5. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
6. Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals.
Govender R; Abrahmsén-Alami S; Larsson A; Folestad S
Eur J Pharm Biopharm; 2020 Apr; 149():58-76. PubMed ID: 31982577
[TBL] [Abstract][Full Text] [Related]
7. Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows.
Verbarendse M; Snyder R; Lakshmipathy U
Cytotherapy; 2023 Oct; 25(10):1107-1112. PubMed ID: 37294247
[TBL] [Abstract][Full Text] [Related]
8. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
9. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
10. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
Dinh A; Stroncek DF
Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
13. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya.
Orwa JA; Keter LK; Ouko SP; Kibwage IO; Rukunga GM
East Afr Med J; 2004 Jun; 81(6):287-92. PubMed ID: 16167675
[TBL] [Abstract][Full Text] [Related]
14. Expanding the reach of commercial cell therapies requires changes at medical centers.
Stroncek DF; Zhang N; Ren J; Somerville R; Dinh A
J Transl Med; 2024 Feb; 22(1):181. PubMed ID: 38374090
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Temperature Excursion Management Program for the Commercial Distribution of Biopharmaceutical Drug Products.
Desai KG; Colandene JD; Adams M
J Pharm Sci; 2020 Jul; 109(7):2131-2144. PubMed ID: 32315663
[TBL] [Abstract][Full Text] [Related]
16. Variations in novel cellular therapy products manufacturing.
Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
[TBL] [Abstract][Full Text] [Related]
17. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
18. Towards a common framework for defining ancillary material quality across the development spectrum.
Ball O; Zylberberg C
Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of rule elements for transportation of cell therapy products among regulations and standards.
Okamura Y; Kano S
Regen Med; 2023 Aug; 18(8):611-622. PubMed ID: 37340930
[TBL] [Abstract][Full Text] [Related]
20. Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar.
Harrison RP; Rafiq QA; Medcalf N
Cytotherapy; 2018 Jun; 20(6):873-890. PubMed ID: 29807726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
